RET C618R

CI-VAR-00000332Explore in graph →CIViC 4786

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Neoplasm1
RET C618R	Selpercatinib	Predictive	D	Supports Sensitivity Response	2	accepted	EID11877 Preclinical data demonstrated Ba/F3 cells transformed with RET p.C618R were sensitive to selpercatinib with an IC50 of 3.5nM. PMID 37376747 · Szymczak et al., 2023 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.